INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 64 filers reported holding INFINITY PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $0 | -100.0% | 359 | -97.4% | 0.00% | – |
| Q3 2022 | $16,000 | +77.8% | 13,652 | -7.0% | 0.00% | – |
| Q2 2022 | $9,000 | -73.5% | 14,685 | -49.2% | 0.00% | – |
| Q1 2022 | $34,000 | -93.8% | 28,931 | -88.0% | 0.00% | – |
| Q4 2021 | $544,000 | +216.3% | 241,936 | +379.1% | 0.00% | – |
| Q3 2021 | $172,000 | +120.5% | 50,493 | +95.5% | 0.00% | – |
| Q2 2021 | $78,000 | +160.0% | 25,827 | +180.2% | 0.00% | – |
| Q1 2021 | $30,000 | – | 9,217 | +921600.0% | 0.00% | – |
| Q2 2020 | $0 | – | 1 | -99.0% | 0.00% | – |
| Q1 2019 | $0 | – | 96 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | – | 96 | 0.0% | 0.00% | – |
| Q3 2018 | $0 | – | 96 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 96 | -99.4% | 0.00% | – |
| Q1 2018 | $32,000 | -66.0% | 15,107 | -67.5% | 0.00% | – |
| Q4 2017 | $94,000 | +9300.0% | 46,496 | +4142.3% | 0.00% | – |
| Q3 2017 | $1,000 | -98.1% | 1,096 | -96.8% | 0.00% | – |
| Q2 2017 | $54,000 | -11.5% | 34,357 | +80.5% | 0.00% | – |
| Q1 2017 | $61,000 | +369.2% | 19,035 | +84.2% | 0.00% | – |
| Q4 2016 | $13,000 | +333.3% | 10,334 | +440.2% | 0.00% | – |
| Q3 2016 | $3,000 | -85.0% | 1,913 | -87.2% | 0.00% | – |
| Q2 2016 | $20,000 | +1900.0% | 14,984 | +4861.6% | 0.00% | – |
| Q1 2016 | $1,000 | -87.5% | 302 | -71.9% | 0.00% | – |
| Q4 2015 | $8,000 | -97.2% | 1,074 | -97.0% | 0.00% | – |
| Q3 2015 | $282,000 | +158.7% | 35,320 | +221.9% | 0.00% | – |
| Q2 2015 | $109,000 | +275.9% | 10,973 | +379.0% | 0.00% | – |
| Q1 2015 | $29,000 | -97.5% | 2,291 | -96.8% | 0.00% | -100.0% |
| Q4 2014 | $1,158,000 | -92.9% | 72,341 | -94.3% | 0.00% | -93.8% |
| Q3 2014 | $16,387,000 | +300.6% | 1,260,466 | +269.7% | 0.02% | +300.0% |
| Q2 2014 | $4,091,000 | +11.2% | 340,931 | +2.0% | 0.00% | 0.0% |
| Q1 2014 | $3,678,000 | +49.1% | 334,271 | +76.2% | 0.00% | +100.0% |
| Q4 2013 | $2,467,000 | -73.9% | 189,714 | -65.8% | 0.00% | -83.3% |
| Q3 2013 | $9,443,000 | +38.6% | 555,453 | +32.0% | 0.01% | +33.3% |
| Q2 2013 | $6,814,000 | – | 420,842 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |